SYSTEMATIC REVIEW/META ANALYSIS
Year : 2022 | Volume
: 28 | Issue : 3 | Page : 175--185
Comparative effectiveness and tolerability of targeted agents combined with chemotherapy in patients with HER2-positive gastroesophageal cancer: A network meta-analysis
Yin-Hong Yan1, Xiao-Yi Lei1, Wei-Ping Hu2
1 Department of Gastroenterology, The First Affiliated Hospital of Xiamen University, Xiamen, China
2 Department of Nephrological, The First Affiliated Hospital of Xiamen University; Nephrological Department, The Fifth Hospital of Xiamen, Xiamen, China
Background: Gastric cancer (GC) or gastroesophageal junction (GEJ) cancer with HER2 overexpression is highly invasive, with a poor prognosis. With the development of new targeted agents, which agents have ideal therapeutic effects must be determined. This network meta-analysis analyzed the effectiveness and tolerability of targeted agents combined with chemotherapy in HER2-positive GC/GEJ cancer.
Methods: Public databases were searched from the date of inception to October 22, 2020. Randomized controlled trials (RCTs) on targeted agent-related regimens for HER2-positive advanced GC or GEJ cancer were included. Subgroup analyses based on publication language, first-line treatment, second/third-line treatment, and HER2 staining intensity were performed.
Results: In total, 13 articles were included. The trastuzumabderuxtecan (TraD) and pertuzumab plus trastuzumab and chemotherapy (PerTraChemo) regimens were considered to have high effectiveness but low tolerability. In the subgroup analysis, PerTraChemo still had high effectiveness with low tolerability as the first-line therapy. As the second- or third-line therapy, TraD and lapatinib plus chemotherapy (LapChemo) had high effectiveness and moderate tolerability. In terms of overall survival (OS) time, PerTraChemo had a relative advantage in the immunohistochemistry (IHC) 2+/in situ hybridization (ISH)+ population, whereas TraD, PerTraChemo, and trastuzumab plus chemotherapy (TraChemo) had a relative advantage in the IHC3+ population.
Conclusion: TraD had relative advantages as the second- or third-line therapy and in the IHC3 + population. PerTraChemo is a potential first-line therapy, but it requires further confirmation because the JACOB phase III clinical trial failed to confirm the superiority of PerTraChemo over TraChemo with regard to OS.
Dr. Wei-Ping Hu
No. 55, Zhenhai Road, Siming District, Xiamen City - 361003
|How to cite this article:|
Yan YH, Lei XY, Hu WP. Comparative effectiveness and tolerability of targeted agents combined with chemotherapy in patients with HER2-positive gastroesophageal cancer: A network meta-analysis.Saudi J Gastroenterol 2022;28:175-185
|How to cite this URL:|
Yan YH, Lei XY, Hu WP. Comparative effectiveness and tolerability of targeted agents combined with chemotherapy in patients with HER2-positive gastroesophageal cancer: A network meta-analysis. Saudi J Gastroenterol [serial online] 2022 [cited 2022 May 20 ];28:175-185
Available from: https://www.saudijgastro.com/article.asp?issn=1319-3767;year=2022;volume=28;issue=3;spage=175;epage=185;aulast=Yan;type=0